ArticleEndocrine2021
The longer the antithyroid drug is used, the lower the relapse rate in Graves' disease: a retrospective multicenter cohort study in Korea.
Article in Endocrine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 30 citations in OpenAlex.
- Treatment outcomes in patients with relapsed Graves' disease.Archives of endocrinology and metabolism · 2026Article
- Relapsed Graves' disease: should continuous low-dose methimazole become a preferred strategy?Archives of endocrinology and metabolism · 2026Article
- Graves' disease: review of disease characteristics, burden, and treatments.Frontiers in endocrinology · 2026Review
- Quality of life in refractory Graves' hyperthyroidism: a cross-sectional study comparing long-term ATDs therapy versus L-T4 replacement after iodine-131.Frontiers in endocrinology · 2026Observational
- Medical Treatment of Hyperthyroidism; Efficacy and Safety Considerations.Archives of Iranian medicine · 2025Review
- High TRAb Titer at Diagnosis Predicts Persistent Positivity and Relapse in Graves' Disease after Prolonged Antithyroid Therapy.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Process to radioactive iodine treatment for Graves' hyperthyroidism: condemned or absolved?Journal of endocrinological investigation · 2025Review
- A short review of current knowledge regarding long-term treatment of Graves' disease with antithyroid drugs.Hormones (Athens, Greece) · 2025Review
- A Predictive Model for Graves' Disease Recurrence After Antithyroid Drug Therapy: A Retrospective Multicenter Cohort Study.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2025Observational
- K-Means Clustering Reveals Long-Term Thyrotropin Receptor Antibody Patterns in Graves' Disease: Insights from a 10-Year Study with Implications for Graves' Orbitopathy.Journal of clinical medicine · 2025Article
- Treatment of Graves' Disease: Faster Remission or Longer but Safe, That Is the Question.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Increased risk of hyperthyroidism induced by immune checkpoint inhibitors in patients with existing or prior Graves' disease: a nested prospective cohort study with propensity score matching.Frontiers in endocrinology · 2025Article
- Thyroid-stimulating immunoglobulin levels during low-dose antithyroid therapy predict Graves' disease relapse.Frontiers in endocrinology · 2025Article
- A 2023 International Survey of Clinical Practice Patterns in the Management of Graves Disease: A Decade of Change.The Journal of clinical endocrinology and metabolism · 2024Article
- Efficacy of Anti-Thyroid Medications in Patients with Graves' Disease.BMC endocrine disorders · 2024Article
- Dynamic Risk Model for the Medical Treatment of Graves' Hyperthyroidism according to Treatment Duration.Endocrinology and metabolism (Seoul, Korea) · 2024Article
- Hyperthyroidism: A Review.JAMA · 2023Review
- The Early Changes in Thyroid-Stimulating Immunoglobulin Bioassay over Anti-Thyroid Drug Treatment Could Predict Prognosis of Graves' Disease.Endocrinology and metabolism (Seoul, Korea) · 2023Article
- Long-term follow-up result of antithyroid drug treatment of Graves' hyperthyroidism in a large cohort.European thyroid journal · 2023Article
- Long-term management of Graves disease: a narrative review.Journal of Yeungnam medical science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCurrent literature suggests 12-18 months of antithyroid drug (ATD) treatment for patients with Graves' disease, but the risk of relapse is high. Although some studies reported better outcomes of long-term ATD treatment, recent data that suggest the optimal treatment duration are limited.
methodsWe performed a multicenter retrospective cohort study of 908 patients newly diagnosed with Graves' disease between 2006 and 2013. The relapse rate according to ATD treatment duration was analyzed.
resultsAfter initial ATD treatment, 338 patients (37.2%) had relapsed. The relapse rate according to ATD treatment duration was 42.4% at 1 year, 38.5% at 2 years, 33.8% at 3 years, 31.7% at 4 years, 30.2% at 5 years, 27.8% at 6 years, and 19.1% at more than 6 years, respectively, demonstrating a significant decreasing trend (p = 0.003). In a multivariable Cox regression analysis, ATD treatment duration was an independent risk factor for relapse (p = 0.043).
conclusionsThe longer that ATD therapy is used, the lower the relapse rate is in patients with Graves' disease. Long-term ATD treatment may be considered in Graves' patients who do not show complications or an economic burden from hyperthyroidism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.